These Innovative Health Techs Are Tackling The Multi-Billion Dollar ADD/ADHD Epidemic

0
1059

Two pioneering companies, Eyecarrot Innovations Corp (OTC: EYCCF, TSX.V: EYC) and Karolinska Development (ST:KDEV), have developed technologies that combat the visual learning disabilities often disguised as ADD.

ADD has been called an epidemic — and it’s spreading fastest among toddlers. In fact, half the children taking Ritalin for ADD/ADHD aren’t even 6 years old yet.[i]

It’s a scary thought. Based on what comprehensive research reveals about genetics and the brain, ADD or ADHD should show up in less than 6% of children[ii].  Meaning that as many as 1.6 million U.S. children deemed to suffer ADD may likely be misdiagnosed. 1.6 million!

In many states, the numbers are off the charts: in Kentucky and North Carolina, 15% of children are supposedly affected.[iii] In the South, 30% of boys are diagnosed with ADD (a rate that exploded since 2003 when schools began to lose funding if too many students fell behind in testing—unless the failing students had a handicap like ADD.[iv]). While nationally, the CDC reports that 11% of school children have been diagnosed with ADD. Almost twice what “should” be foun

Only in a few states, such as California and Colorado, do the statistics match the evidence.

That’s where companies like Eyecarrot Innovations (OTC: EYCCF, TSX.V: EYC) and Karolinska Development (ST:KDEV) come in.

 

Their groundbreaking therapies help reverse symptoms often mistaken for ADD/ADHD – and we believe tackling this high-profile issue will power their stock forward.

Eyecarrot and Karolinska are perfectly poised to have a significant impact on the $12 billion ADD drug treatment market!

Why 1.6 Million Children Diagnosed With
ADD/ADHD Should Not Be Prescribed Medication

As Pulitzer- Prize-wining journalist Alan Schwartz puts it in his best seller ADHD Nation, “ADHD itself is not an epidemic—ADHD misdiagnosis is an epidemic.”

Schwartz goes on to say, “If the system functioned in such a way as to stay anywhere near the 5% diagnosis rate that the American Psychiatric Association’s official definition suggests, we wouldn’t be in this mess.”

Eyecarrot Innovations Corp and Karolinska intend to get children out of the mess. And they are succeeding because some of the misdiagnosed children have other cognitive problems, especially with memory. Even more of them actually have vision processing problems.

Sweden’s prestigious Karolinska Development Institute (Stockholm: KDEE) promotes pharmaceutical research.

“Today, 1 in 4 people — that’s nearly 2 billion people worldwide— have visual performance issues that go beyond the ability to see clearly. Things like reading and learning challenges, poor athletic performance, and incomplete recovery from concussions or other traumatic brain injuries.”

—Adam Cegielski, Eyecarrot founder

Their Cogmed program to train working memory has been tested in 25 different studies since 2002. In 2016, the journal, Psychology, concluded that  “Cogmed© WM training could be an effective training program for children with neurodevelopmental problems, with the best results for children with ADHD or learning problems.”

The other pioneer in this cause is a young Canadian company, Eyecarrot Innovations Corp (OTC: EYCCF or TSX.V: EYC).  Its mission is vision-training systems to overcome learning, neurological and motor difficulties and is taking direct aim at helping the children who have been wrongly diagnosed because they have a condition that mimics ADD/ADHD.

The authoritative DSM-IV, Diagnostic and Statistical Manual of Mental Disorders has a checklist of 18 possible symptoms. A child has to show 6 or more of them. They have to be present for more than 6 months, and show up in at least two different environments. [v]

Unfortunately, 15 of those 18 traits also show up in children with vision-related learning disabilities!

For instance, children with “convergence insufficiency” are three times more likely to be diagnosed with ADD.  This is a very common condition where the eyes don’t continue to cooperate in tracking objects are they grow nearer.  With the right tests, it is easily diagnosed. It affects about 10% of children. So they hate to read. They talk when they should be listening. They do badly in school… and then someone says they have ADD.

Unfortunately a standard vision exam does not include those simple tests. Someone has to be alert to the potential problem. And then they can fix it. That’s where Eyecarrot Innovations helps.

Eyecarrot Innovations makes professional visual training programs for optometrists and eye care professionals to use in helping children, athletes, and adults overcome vision disabilities.

Convergence insufficiency is just one type. In total, up to 20% of children may be affected by some degree of a vision-related learning disorder that can be helped with guided therapy instead of drugs, operations, or glasses.

The Binovi Platform Tackles Learning Disabilities and Traumatic Brain Injuries With Continuous, High-Level, Neuro-Optic Training

Binovi is Eyecarrot Innovation’s professional grade tablet-based system for visual training and record keeping, and is distributed exclusively to eye-care professionals with advanced training in vision therapy.  The Binovi platform is unique in that it offers practitioners the hardware and software necessary to create customized strategies for treating patients with a wide variety of needs.

In addition to the vast ADD market, Eyecarrot Innovations’ Binovi program is a suite of more than 100 visual training exercises that help patients in at least seven different multi-billion dollar markets. For instance…

  • Convergence insufficiency—affects 2.5% to 13% of total population
  • Amblyopia—“lazy eye” where one eye does not coordinate with the brain affects 2-3% of the population
  • Strabismus—1.2 million surgeries a year, many that could be avoided with training instead
  • Athletes and active adults may also suffer from effects that follow concussions and traumatic brain injury—3 to 4 million people a year
  • Sports performance—is taking visual training seriously and the top five sports involve 75 million participants
  • Healthy Aging—eye changes affect 36 million drivers over 65
  • ADD/ADHD Misdiagnosis that could be corrected—1.6 million children

Eyecarrot Innovations’ Prestigious Heritage Is a Strong Marketing Advantage

Investors should think of Eyecarrot Innovations as a medical device stock, with all the phenomenal market-beating potential that class has shown in the past.

Eyecarrot Innovations has deep connections to the visual medical community. The system is based on the work of visionary medical device pioneer Mr. Harry Wayne, who invented the Wayne Saccadic Fixator (WSF).

Before his death at age 97, Wayne was known in the medical community for showing up at the annual meeting of the College of Optometrists in Vision Development, and revealing new inventions ranging from the WSF to the Perceptuomotor/Talking Pen, to the Directional Sequencer.

Eyecarrot Innovations purchased Wayne Engineering to bring Harry Wayne’s work forward.

In 2017, Eyecarrot Innovations began offering the Binovi training program to doctors and clinics, and is in the market to replace the 4,000+ Saccadic Fixators currently in use across the country.

Now is the time for investors to catch up, as sales should begin to explode in the coming year.

Eyecarrot Innovations Is A Boon to Vision Practices and Patients

Vision training… for ADD, concussions, aging eyes, sports performance… is a big business. Only some of the 146,000 optometry employees are trained to perform it, but we believe that number will rise as the income potential becomes obvious.

Eyecarrot Innovations’ Binovi makes it easy for developmental optometrists to plan a course of treatment, teach exercises, prescribe home drills, and monitor progress. This is a particularly attractive area for independent optometrists who are seeing glass and contact lens sales being lost to online competitors and large chains draw off their customers.

Visual training is a high-income practice. And we think thousands of optometrists will benefit from the ease and efficiency of Binovi to capture this important income stream:[vi]

  • Basic functional visual exam $220
  • Exam involving concussion or head trauma $350
  • Charge per visit for visual therapy $152
  • Charge for typical full course of treatment $1000 to $7000 per patient

This is medical practice independents can offer that the chains like Walmart will miss. This is why Mr. Harry Wayne and his successors at Eyecarrot Innovations’ strong ties to the medical community are so valuable to the future of EYCCF.

Now It’s About Leveraging Professionalism—6 Reasons Eyecarrot Innovations’ Binovi is Destined to Succeed

  1. It’s In the Doctors’ HandsThe Binovi program brings vision therapy home for millions of potential users, but this is serious training and it’s only available through doc
  2. Excellence Is a Requirement—Before using the system, doctors must apply and present credentials to prove there are trained vision therapists.
  3. This Software-Driven Tool Is a Medical Device—every year some medical device seems to top the charts for best investment of the year. Already this year, companies like Abiomed and Novocure are up more than 100%.
  4. Global Potential Is a Given. Eyecarrot Innovations treats visual challenges that affect children, accident victims, and athletes worldwide. It is already expanding to optometrists in Australia alongside Canada and the US.
  5. More than 100 Million Potential Users in the US Alone. Drivers over 65, athletes hoping to improve reactions and hand-eye coordination, children diagnosed with ADD (and adults!), patients with concussions or head traumas… visual training is a vital, widely needed service for them all.
  6. Joining The $308 Billion e-Health TrendThe greatest change in medicine now is the role that Internet-based medicine and information has carved out. The Binovi platform uses the best of information technology to deliver. And after 2 years of product development, EyeCarrot Innovations just signed multiple distribution deals to move their hardware into commercialization

Look First, Then Tell Your Broker You Have a Great Idea

You can find out everything you need to know about Eyecarrot Innovations Corp (TSX.V: EYC or OTC: EYCCF) at the company’s own website. You will see how the Binovi platform is used. Why patients do better with Binovi Coach in their hands than they do with traditional “home-alone” drills. Why doctors love it and see this as a way to expand and improve their practices.

Eyecarrot Innovations and Binovi are alone out front. While visual drills are widely used, optometrists have been relying on show and tell—then sending patients home with handouts. We can add more about the hardware here, and how it gives practitioners data so we can measure performance changes over time.

Eyecarrot Innovations gives doctors a ready suite of exercises, a coaching system, tracking and reporting. All of which improve doctors’ professional impression on their patients and markedly upgrade their earning potential.

Take a look at their corporate presentation and watch the videos. Then tell your broker that you’ve found something special.

Available in the US on the OTC market, symbol EYCCF, and in Canada on the TSX, symbol EYC.

[i] https://latitudes.org/tag/ritalin/ according to CDC

[ii] https://www.nytimes.com/2013/12/15/health/the-selling-of-attention-deficit-disorder.html

[iii] https://www.psychiatryadvisor.com/adhd/a-true-adhd-epidemic-or-an-epidemic-of-overdiagnosis/article/429034/

[iv] https://www.scientificamerican.com/article/big-pharma-s-manufactured-epidemic-the-misdiagnosis-of-adhd/

[v] http://www.minnesotavisiontherapy.com/adhd-add-vision

[vi] fees from

http://www.thevisiontherapycenter.com/costs-the-vision-therapy-center

 

 

This report is for information purposes only, and is neither a solicitation or recommendation to buy nor an offer to sell securities. Financials Trend is not-a-registered-investment-advisor. Financials Trend is not a broker-dealer. Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. Financials Trend accepts no liability for any losses arising from an investor's reliance on the use of this material. Financials Trend sometimes gets compensated up to one hundred and fifty thousand dollars per month for featuring particular stocks. See site disclaimer for complete compensation. Financials Trend and its affiliates or officers currently hold no shares of these stocks. Financials Trend and its affiliates or officers will purchase and sell shares of common stock of these stocks, in the open market at any time without notice. Financials Trend will not update its purchases and sales of these stocks in any future postings on Financials Trend's websites. Certain information included herein is forward-looking within the context of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. The words "may", "would," "will," "expect," "estimate," "anticipate," "believe," "intend," " project," and similar expressions and variations thereof are intended to identify for ward-looking statements. Such forward- looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. *Financials Trend does not set price targets on securities. Never invest into a stock discussed on this web site or in this email alert unless you can afford to lose your entire investment. 

financialstrend.com